EUROPEAN MARKETS FOR ERECTILE DYSFUNCTION DRUGS, DEVICES, AND THERAPIES

175 Pages | 39 Exhibits | 2008 Analysis | Forecasts Through 2011 Product Family: Market Reports




OVERVIEW:
Erectile dysfunction (ED) affects more than 150 million men worldwide, including more than 20 million in Europe and 30 million or more in the U.S. The number of men suffering from ED is expected to double by the year 2025.

Due to their effectiveness and convenience, prescription oral medications remain the first-line-of-treatment for the majority of men with ED, generating a worldwide market for oral ED drugs that is worth more than $3 billion. Problems with the current oral ED drug therapy include undesirable side effects, contraindications, and lack of effectiveness in some patients; however, it is expected that promising new topical ED drugs will be launched in Europe within the next 5 years--some of which will be offered over-the-counter. Importantly, these new topical ED drugs may offer "spontaneity" to a large, underserved population of men with mild-to-moderate forms of ED, while sparing them the "embarrassment" of seeking a physician's prescription. Additionally, superior, next-generation oral ED drugs are expected to enter the market within the coming decade.

The European market for ED treatment products, including drugs and penile implants, was valued at approximately $1,085.5 million in 2007. Sales of ED treatment products in Europe are expected to increase at a healthy compound annual rate of 9.3% over the next half-decade, reaching an estimated $1,548.5 million in the year 2011.

This dynamic, new report from Medtech Insight includes analyses of products, current and emerging markets, competitors, and opportunities in the European ED drugs, devices, and therapies market.

Covered topics in this report include a discussion of the healthcare markets of France, Germany, Italy, Spain, the U.K., and the Benelux countries (Belgium, the Netherlands, and Luxembourg), an overview of ED disorders and management options; emerging topical ED agents, existing/emerging oral ED drugs, emerging/investigational surgical ED treatments, injectable/intraurethral ED therapies, penile implants, and vacuum constriction devices, among others.

TABLE OF CONTENTS:

EXECUTIVE SUMMARY

i.    Causes

ii.    Oral Drug Therapy

iii.   Topical Agents

iv.   Injectable and Intraurethral Agents

v.   Vacuum Constriction Devices

vi.   Penile Implants

vii.  European Market for Erectile Dysfunction Drugs and Penile Implants

viii. Methodology

 

Exhibit ES-1:    Comparison of Cialis, Levitra, and Viagra

Exhibit ES-2:    2008, Selected Emerging Erectile Dysfunction Drugs

Exhibit ES-3:    Benefits and Risks of Penile Implants

Exhibit ES-4:    Europe, Erectile Dysfunction Treatment Products, Combined Market Forecast, 2006-2011

 

 

1. EUROPEAN HEALTHCARE MARKETS

1.1 The European Union

1.1.1 A Common Currency

1.1.2 Regulatory Policies

1.1.3 Reimbursement

1.1.4 Healthcare Spending

1.2 Selected European National Healthcare Profiles

1.2.1 France

1.2.1.1 Healthcare Organization and Reform

1.2.1.2 Hospital Services

1.2.1.3 Medical Device Reimbursement

1.2.2 Germany

1.2.2.1 Healthcare Organization and Reform

1.2.2.2 Hospital Services

1.2.2.3 Medical Device Reimbursement

1.2.3 Italy

1.2.3.1 Healthcare Organization and Reform

1.2.3.2 Hospital Services

1.2.3.3 Medical Device Reimbursement

1.2.4 Spain

1.2.4.1 Healthcare Organization and Reform

1.2.4.2 Hospital Services

1.2.4.3 Medical Device Reimbursement

1.2.5 United Kingdom

1.2.5.1 Healthcare Organization and Reform

1.2.5.2 Hospital Services

1.2.5.3 Medical Device Reimbursement

1.2.6 Benelux

1.2.6.1 Healthcare Organization and Reform

1.2.6.1.1 Belgium

1.2.6.1.2 Luxembourg

1.2.6.1.3 The Netherlands

1.2.6.2 Hospital Services

1.2.6.3 Medical Device Reimbursement

 

Exhibit 1-1:      European Union, Medical Devices Risk Classification System

Exhibit 1-2:      2007, Europe, Population Statistics, Selected Countries

Exhibit 1-3:      France, Selected National Healthcare Statistics

Exhibit 1-4:      Germany, Selected National Healthcare Statistics

Exhibit 1-5:      Italy, Selected National Healthcare Statistics

Exhibit 1-6:      Spain, Selected National Healthcare Statistics

Exhibit 1-7:      United Kingdom, Selected National Healthcare Statistics

Exhibit 1-8:      Belgium, Selected National Healthcare Statistics

Exhibit 1-9:      Luxembourg, Selected National Healthcare Statistics

Exhibit 1-10:    The Netherlands, Selected National Healthcare Statistics

 

2. CLINICAL OVERVIEW OF ERECTILE DYSFUNCTION

2.1 Causes

2.2 Diagnosis and Treatment

2.2.1 Oral Drug Therapy

2.2.2 Injectable/Intraurethral Drug Therapy

2.2.3 Vacuum Pump Therapy

2.2.4 Surgery/Penile Implantation

2.3 Emerging Treatments and Prevention

 

3. ERECTILE DYSFUNCTION TREATMENT PRODUCTS MARKET

3.1 Drug Therapy

3.1.1 Oral Agents

3.1.1.1 Cialis:  Eli Lilly

3.1.1.2 Levitra:  Bayer HealthCare/Bayer

3.1.1.3 Viagra:  Pfizer

3.1.2 Injectable and Intraurethral Agents

3.1.2.1 Caverject:  Pfizer

3.1.2.2 MUSE:  VIVUS

3.1.3 Alternative Treatments

3.1.3.1 Testosterone Replacement Therapy

3.1.3.2 Yohimbine

3.1.3.3 Over-the-Counter Herbal Treatments

3.1.4 Emerging Drugs

3.1.4.1 Oral Agents

3.1.4.1.1 Zydena:  Dong-A PharmTech/Dong-A Pharmaceutical

3.1.4.1.2 Phosphodiesterase Type 5 Inhibitors: NitroMed

3.1.4.1.3 Lescol:  Novartis

3.1.4.1.4 UK-369003:  Pfizer

3.1.4.1.5 Mvix:  SK Chemicals/SK Holdings

3.1.4.1.6 Avanafil:  VIVUS

3.1.4.2 Centrally Acting Agents

3.1.4.2.1 Intranasal Apomorphine: Nastech Pharmaceutical

3.1.4.2.2 Bremelanotide: Palatin Technologies

3.1.4.3 Topical Agents

3.1.4.3.1 MED2002:  Futura Medical
and SSL International

3.1.4.3.2 CSD500:  Futura Medical
and SSL International

3.1.4.3.3 Topically Applied Alprostadil
Cream:  NexMed

3.2 Penile Implants

3.2.1 Inflatable Implants

3.2.1.1 The AMS 700 and the AMS Ambicor: American Medical Systems

3.2.1.2 The Excel Inflatable Penile Prosthesis: Coloplast

3.2.1.3 The Titan Inflatable Penile Prosthesis: Coloplast

3.2.2 Noninflatable Implants

3.2.2.1 The AMS DURA II and the AMS 650/600M: American Medical Systems

3.2.2.2 The Genesis Penile Prosthesis:  Coloplast

3.3 Vacuum Constriction Devices

3.3.1 The SOMAerectStf and the Vitality Over-the-Counter System:   Augusta Medical Systems

3.3.2 The Osbon ErecAid Vacuum Therapy System: Timm Medical Technologies/Plethora Solutions

3.3.3 The BOSS 2000-3 and MVP-700 Vacuum Systems: Post-T-Vac Medical

3.4 Other Devices

3.4.1 ACTIS:  VIVUS

3.5 Investigational/Emerging Surgical Treatments

3.5.1 Nerve-Sparing Prostatectomy/Nerve Grafting

3.6 Market Analysis

3.6.1 Drug Therapy

3.6.1.1 Patient Volumes Forecast

3.6.1.2 Market Forecast

3.6.1.3 Competitive Analysis

3.6.2 Penile Implants

3.6.2.1 Procedure Volumes Forecast

3.6.2.2 Market Analysis

3.6.2.3 Competitive Analysis

3.6.3 Combined Market Forecast

 

 

Exhibit 3-1:      Comparison of Cialis, Levitra, and Viagra

Exhibit 3-2:      Viagra, Patient Satisfaction Rates at One to Four Years

Exhibit 3-3:      2008, Selected Emerging Erectile Dysfunction Drugs

Exhibit 3-4:      Benefits and Risks of Penile Implants

Exhibit 3-5:      Advantages and Disadvantages of the AMS 700 Three-Piece Inflatable Penile Implant

Exhibit 3-6:      Advantages and Disadvantages of the AMS Ambicor Two-Piece Inflatable Penile Implant

Exhibit 3-7:      Coloplast's Excel Inflatable Penile Prosthesis

Exhibit 3-8:      Advantages of Coloplast's Titan Inflatable Penile Prosthesis

Exhibit 3-9:      Coloplast's Malleable Genesis Penile Prosthesis

Exhibit 3-10:    Augusta Medical Systems' SOMAerectStf Vacuum Therapy System

Exhibit 3-11:    Augusta Medical Systems' Vitality Over-the-Counter Treatment System

Exhibit 3-12:    Timm Medical Technologies' Osbon ErecAid Vacuum Therapy Systems

Exhibit 3-13:    Post-T-Vac Medical's BOSS 2000-3 and MVP 700 Vacuum Constriction Devices

Exhibit 3-14:    VIVUS' ACTIS Device

Exhibit 3-15:    Patented Implantable Neurostimulation Device for Erectile Dysfunction

Exhibit 3-16:    Clinical Study of Energy-Based Treatment of Erectile Dysfunction

Exhibit 3-17:    Europe, Erectile Dysfunction Drug Therapy, Patient Volumes Forecast, 2006-2011

Exhibit 3-18:    Europe, Erectile Dysfunction Drug Therapy, Market Forecast, 2006-2011

Exhibit 3-19:    2006, Europe, Erectile Dysfunction Drug Therapy Market, Share by Supplier

Exhibit 3-20:    2007, Europe, Erectile Dysfunction Drug Therapy Market, Share by Supplier

Exhibit 3-21:    Europe, Penile Prosthesis Implantation, Procedure Volumes Forecast, 2006-2011

Exhibit 3-22:    Europe, Penile Implants, Market Forecast, 2006-2011

Exhibit 3-23:    2006, Europe, Penile Implants Market, Share by Supplier

Exhibit 3-24:    2007, Europe, Penile Implants Market, Share by Supplier

Exhibit 3-25:    Europe, Erectile Dysfunction Treatment Products, Combined Market Forecast, 2006-2011

 

4. COMPANY PROFILES

4.1    American Medical Systems Holdings, Inc.

4.2    Augusta Medical Systems LLC

4.3    Bayer AG

4.4    Coloplast AS

4.5    Futura Medical PLC

4.6    GlaxoSmithKline PLC

4.7    Eli Lilly and Company

4.8    NexMed, Inc.

4.9    Palatin Technologies, Inc.

4.10  Pfizer, Inc.

4.11  SK Chemicals/SK Holdings Company LTD

4.12  SSL International PLC

4.13  VIVUS, Inc.

 

APPENDIX:  COMPANY LISTING



COMPANIES COVERED:

  1. American Medical Systems Holdings, Inc.
  2. Augusta Medical Systems LLC
  3. Bayer AG
  4. Coloplast AS
  5. Futura Medical PLC
  6. GlaxoSmithKline PLC
  7. Eli Lilly and Company
  8. NexMed, Inc.
  9. Palatin Technologies, Inc.
  10. Pfizer, Inc.
  11. SK Chemicals/SK Holdings Company LTD
  12. SSL International PLC
  13. VIVUS, Inc.
Contact Us

Need help finding medtech research? Let us help you!